Home › Multiple Myeloma › Wisconsin › Milwaukee
Pag-aaral pangklinika para sa Multiple Myeloma sa Milwaukee, WI
Isang pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Milwaukee. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Nagre-recruitPhase 3
- Research Site, Milwaukee
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Nagre-recruitPhase 1/2
- Medical College of Wisconsin, Milwaukee
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- Medical College Of Wisconsin, Milwaukee
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Nagre-recruitPhase 4
- Froedtert Memorial, Milwaukee
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1/2
- The Medical College of Wisconsin, Milwaukee
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Nagre-recruitPhase 2
- Aurora Cancer Care Milwaukee, Milwaukee
- Aurora St. Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- at 4 pa
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Nagre-recruitPhase 3
- Medical College of Wisconsin, Milwaukee
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Nagre-recruitPhase 3
- Medical College of Wisconsin, Milwaukee
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1/2
- Research Site, Milwaukee
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Nagre-recruitPhase 3
- Aurora Cancer Care-Milwaukee, Milwaukee
- Ascension Southeast Wisconsin Hospital-Saint Joseph-Milwaukee, Milwaukee
- Ascension Columbia Saint Mary's Hospital-Milwaukee Campus, Milwaukee
- at 13 pa
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Nagre-recruitPhase 1/2
- Research Site, Milwaukee
Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
Nagre-recruitPhase 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Nagre-recruitPhase 2
- MCW-Clinical Cancer Center at Froedtert Hospital Campus, Milwaukee
Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
Nagre-recruit
- Medical College of Wisconsin, Milwaukee
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Nagre-recruitPhase 3
- Froedtert Memorial Lutheran Hospital, Milwaukee
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Nagre-recruitPhase 2
- Medical College of Wisconsin, Milwaukee
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Nagre-recruitPhase 1
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
Nagre-recruitPhase 2
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Nagre-recruitObservasyonal na pag-aaral
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Froedtert and the Medical College of Wisconsin, Milwaukee
Pag-aaral para sa Multiple Myeloma sa ibang lungsod
- New York City, NY60 pag-aaral
- Boston, MA42 pag-aaral
- Atlanta, GA41 pag-aaral
- Houston, TX38 pag-aaral
- Durham, NC37 pag-aaral
- Nashville, TN32 pag-aaral
- Denver, CO27 pag-aaral
- Rochester, MN24 pag-aaral
- St. Louis, MO24 pag-aaral
- Columbus, OH24 pag-aaral
- Baldwin Park, CA23 pag-aaral
- Chicago, IL22 pag-aaral
Iba pang pag-aaral sa Milwaukee
- Kanser sa Suso23 pag-aaral
- Non-Small Cell Lung Cancer22 pag-aaral
- Kanser (lahat ng uri)22 pag-aaral
- Kanser sa Baga21 pag-aaral
- Kanser sa Prostate20 pag-aaral
- Follicular Lymphoma19 pag-aaral
- Kanser sa Pancreas18 pag-aaral
- Non-Hodgkin Lymphoma18 pag-aaral
- Kanser sa Ovary17 pag-aaral
- Acute Myeloid Leukemia17 pag-aaral
- Burkitt Lymphoma16 pag-aaral
- Pagkabigo ng Puso16 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.